Evaluation of the Reveal® AST (SPECIFIC) for Antimicrobial Susceptibility Testing from Positive Blood Culture Spiked with Carbapenem-Resistant Isolates
Pathogens · 2024
DOI: 10.3390/pathogens13090722 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Pathogens, 2024. Verfasst von Delphine Girlich und 9 weiteren Autor:innen. Beteiligte Einrichtung: Team "Resist" UMR1184 Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB), INSERM, Faculty of Medicine, Paris-Saclay Uni…. Hauptthemen laut MEDLINE: Microbial Sensitivity Tests, Blood Culture, Anti-Bacterial Agents, Carbapenems. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, public grant “France 2030”, Specific Diagnostic.
Abstract (Originalsprache)
As bloodstream infections and associated septic shock are common causes of mortality in hospitals, rapid antibiotic susceptibility testing (AST) performed directly on positive blood cultures is needed to implement an efficient therapy in clinical settings. We evaluated the Reveal® rapid AST system on a collection of 197 fully characterized carbapenem-resistant Enterobacterales, including 177 carbapenemase producers (CPE) spiked in blood culture bottles. The clinical categorization based on the Minimal Inhibitory Concentration (MIC) determination of eighteen antimicrobial molecules was compared to the clinical categorization based on the disk diffusion assay as a reference. The Reveal AST system provided results within a mean time to result of 5 h. Overall, the categorical agreement (CA) between the two techniques was 94.1%. The rates of very major errors (VMEs), major errors (MEs) and minor errors (mEs) were 3.8%, 3.7% and 5.6%, respectively. Imipenem was the antimicrobial with the lowest CA rate (78.7%), with rates of 15% VMEs and 10.7% MEs, but the performances were better when considering only the non-CPE category (CA of 89%). On this resistant collection of Enterobacterales with numerous acquired β-lactamases, the Specific Reveal assay proved to be useful for a rapid determination of AST compatible with a quick adaptation of the patient’s antimicrobial treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Team "Resist" UMR1184 Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB), INSERM, Faculty of Medicine, Paris-Saclay University, 94270 Le Kremlin-Bicêtre, France.
- Bacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, 94270 Le Kremlin-Bicêtre, France.
- Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales, 94270 Le Kremlin-Bicêtre, France.
- Specific Diagnostic, Mountain View, CA 94043, USA.
- Next Gen Diagnostics, Cambridge CB10 1SA, UK.
ORCID-Profile: Delphine Girlich, Agnès B Jousset, Thierry Naas, Laurent Dortet
Förderung
- Agence Nationale de la Recherche
- public grant “France 2030”
- Specific Diagnostic
Zitieren
APA
Girlich, D., Jousset, A. B., Emeraud, C., Rezzoug, I., Burwell, R., Singh, P., Rhodes, P. A., Naas, T., Bonnin, R. A., & Dortet, L. (2024). Evaluation of the Reveal® AST (SPECIFIC) for Antimicrobial Susceptibility Testing from Positive Blood Culture Spiked with Carbapenem-Resistant Isolates. Pathogens. https://doi.org/10.3390/pathogens13090722
Vancouver
Girlich D, Jousset AB, Emeraud C, Rezzoug I, Burwell R, Singh P, et al. Evaluation of the Reveal® AST (SPECIFIC) for Antimicrobial Susceptibility Testing from Positive Blood Culture Spiked with Carbapenem-Resistant Isolates. Pathogens. 2024. doi:10.3390/pathogens13090722
BibTeX
@article{Girlich2024,
author = {Girlich, Delphine and Jousset, Agnès B and Emeraud, Cécile and Rezzoug, Inès and Burwell, Reece and Singh, Pragya and Rhodes, Paul A and Naas, Thierry and Bonnin, Rémy A and Dortet, Laurent},
title = {Evaluation of the Reveal® AST (SPECIFIC) for Antimicrobial Susceptibility Testing from Positive Blood Culture Spiked with Carbapenem-Resistant Isolates},
journal = {Pathogens},
year = {2024},
doi = {10.3390/pathogens13090722}
}
EUVIMED